NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
Share price
−$25.73 (−88.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Anbio Biotechnology grew revenue 5.6% to $8.65M over fiscal 2025. Operating income rose 189.1% to $5.77M, moving the operating margin from 24.4% to 66.7%.
Revenue
$8.65M
+5.6% vs. a year earlier
Operating income
$5.77M
+189.1% vs. a year earlier
EPS, diluted
$0.15
+162.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 22.2
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $8.65M
- Net income
- $6.40M
- EPS, diluted
- $0.15
Five years at a glance
Fiscal years 2021 to 2025, USD
Revenue
$8.65M+5.6% YoY
Gross profit
$7.54M+28.2% YoY
Operating income
$5.77M+189.1% YoY
Net income
$6.40M+169.9% YoY
EPS, diluted
$0.15+162.5% YoY
Reported period